Campbell Soup Co. vs DexCom, Inc. — how do they compare? Campbell Soup Co. trades at $19.15 (market cap $5.78B), while DexCom, Inc. trades at $84.8 (market cap $31.86B). The key difference: DexCom, Inc. is far larger — about 5.5× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays a 5.16% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and DexCom, Inc. for 62 Days on average.
| CPB | DXCM | |
|---|---|---|
Market Cap | $5.78B | $31.86B |
Volume | 11,705,427 | 3,607,070 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $92.34 |
52-Week Low | $18.90 | $54.84 |
Typical Hold Time | 98 Days | 62 Days |
Enterprise Value | $12.83B | $31.32B |
Dividend Yield | 5.16% | — |
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $18.90, down 0.53% with bearish technical signals. The company reported mixed Q2 2026 earnings, beating expectations but showing margin pressure. Recent dividend cut of 36% and workforce reduction signal turnaround efforts amid declining profitability. Valuation appears reasonable with P/E of 14.79 and P/S of 0.6, but revenue growth remains challenged.
The outlook remains cautious with analyst consensus leaning heavily toward Hold (58.62%). While cost-saving initiatives and balance sheet improvements provide some support, persistent margin compression and competitive pressures create headwinds. The stock trades near the lower end of analyst targets ($18-22), offering limited upside potential amid ongoing operational challenges.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →